Clinical trial
A Prospective Multi-Site Open Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)
NCT05414747 is registered in ClinicalTrials.gov with BioFirst Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Multi-Site Open Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)
- Lead sponsor
- BioFirst Corporation
- Phase
- Not applicable
- Overall status
- Suspended
- Start date
- April 15, 2023
- Completion date
- December 15, 2025
- Enrollment
- 40 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.